📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-28 16:19
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
KMC Speciality Q1 Total Income Up 39% to ₹93.6 Cr; PAT Surges 120% to ₹16.6 Cr
KMC Speciality Hospitals released its Q1 FY27 investor presentation, reporting a 39% YoY increase in Total Income to ₹93.6 Cr (compared to ₹67.4 Cr in Q1 FY26). Operating EBITDA rose 76% YoY to ₹30.3 Cr with margins expanding from 25.6% to 32.4%. Profit After Tax (PAT) surged 120% YoY to ₹16.6 Cr from ₹7.5 Cr, reflecting high operating leverage. Operational metrics improved with Occupied Bed Days up 25% YoY to 25,732 and Blended ARPOB rising 11% YoY to ₹34,214.
Confidence: HIGH
What changedKMC Speciality Hospitals published its comprehensive Q1 FY27 operational and financial investor presentation.
Why it mattersDemonstrates operating leverage and margin expansion following the operationalization of the 200-bed Mother & Child care facility, translating into strong top-line and bottom-line expansion.
Q1 FY27 Total Income: ₹93.6 CrQ1 FY27 EBITDA: ₹30.3 CrQ1 FY27 PAT: ₹16.6 CrBlended ARPOB: ₹34,214Occupied Bed Days: 25,732
📅 Short termPositive sentiment driven by strong Q1 operational metrics, significant EBITDA margin expansion to 32.4%, and robust volume gains.
📈 Long termCapacity utilization of the expanded 450-bed infrastructure and focus on high-margin tertiary specialties (organ transplants and neurosciences) support healthy return ratios and medium-term growth.
⚠ Risk flags
- Geographic concentration risk with primary operations focused in and around Tiruchirapalli (Tamil Nadu)
- Shortage or retention risk for specialized clinical talent/surgeons
Key Highlights
Total Income grew 39% YoY to ₹93.6 Cr in Q1 FY27 from ₹67.4 Cr in Q1 FY26.
EBITDA surged 76% YoY to ₹30.3 Cr with EBITDA margin expanding by 680 bps to 32.4%.
Net profit (PAT) grew 120% YoY to ₹16.6 Cr, maintaining a 17.7% net margin.
Occupied bed days increased 25% YoY to 25,732 while Blended ARPOB rose 11% YoY to ₹34,214.
👀 What to Watch
Track occupancy ramp-up across the 200-bed Maa Kauvery facility and monitor whether ARPOB growth and EBITDA margins (>30%) remain sustainable in subsequent quarters.
Rs 519 Cr Capex Approved to Add 591 Beds in Trichy and Bengaluru
KMC Speciality Hospitals has approved a massive expansion plan involving a total investment of Rs 519 crore to add 591 beds across Trichy and Bengaluru. The Trichy campus will see an addition of ~500 beds through a new super-speciality block and additional floors, while a new 91-bed asset-light facility will mark the company's entry into the Bengaluru market. This capex is highly material, representing approximately 157% of the company's TTM revenue and 247% of its current net worth. The projects are scheduled for phased commissioning between Q2 FY28 and Q2 FY30, funded through internal accruals and debt.
Confidence: HIGH
What changedThe company has transitioned from a single-location focus in Trichy to a multi-city strategy with a plan to more than double its total bed capacity.
Why it mattersThis expansion provides a significant long-term revenue growth runway for a company currently operating at high occupancy (up to 98% in some blocks), though it will require substantial capital expenditure relative to its current balance sheet size.
Total Capex: Rs 519 crCapex vs TTM Revenue: ~157%Total New Beds: 591Existing Bed Capacity: 450Final Phase Completion: Q2 FY30
📅 Short termThe announcement is likely to be viewed positively by the market as it provides clear growth visibility, though no immediate impact on earnings is expected given the FY28-FY30 timelines.
📈 Long termIf executed successfully, this expansion could structurally re-rate the company by significantly increasing its scale and diversifying its geographic footprint beyond Trichy.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for large-scale construction
- Potential balance sheet strain from debt funding
- Long gestation period before new beds contribute to revenue
Key Highlights
Total investment of Rs 519 crore approved for capacity expansion across three projects
Bed capacity to increase by ~131%, adding 591 new beds to the existing 450-bed capacity
Entry into Bengaluru with a 91-bed leased Mother & Child facility expected by Q2 FY28
Trichy Super-Speciality block (400 beds) involves a Rs 422 crore investment, including land
Funding to be managed through a combination of internal accruals and term debt
👀 What to Watch
Monitor the company's debt-to-equity ratio as it begins drawing down loans for this large-scale project, and track the execution timeline of the Bengaluru facility which is the nearest-term growth driver (Q2 FY28).
107% YoY Profit Growth: KMC Speciality Hospitals Reports Strong Q1 FY27 Results
KMC Speciality Hospitals (India) Ltd reported a robust performance for the quarter ended June 30, 2026, with revenue from operations growing 36.9% YoY to ₹91.72 cr. Net profit surged by 107.1% YoY to ₹16.57 cr, up from ₹8.0 cr in the same period last year. This growth is primarily driven by the ramp-up of the new 200-bed Mother & Child care block and high-end specialty programs. Operating margins remain healthy at approximately 31%, reflecting strong operational efficiency and pricing power in specialized tertiary care.
Confidence: HIGH
What changedThe company has successfully scaled its operations following the addition of a 200-bed block, resulting in a significant jump in both revenue and profitability compared to the previous year.
Why it mattersThe results validate the company's expansion strategy into specialized tertiary care (Mother & Child, Transplants), demonstrating that the new capacity is being absorbed efficiently without diluting margins.
Revenue (Q1 FY27): ₹91.72 crNet Profit (Q1 FY27): ₹16.57 crYoY Revenue Growth: 36.9%YoY Net Profit Growth: 107.1%Quarterly Revenue vs TTM Revenue: 27.7%
📅 Short termThe stock is likely to react positively in the short term due to the substantial earnings beat and margin sustainability.
📈 Long termThe structural outlook remains positive as the company leverages its expanded 450-bed capacity and established brand legacy in the Trichy region to capture growing demand for specialized healthcare.
⚠ Risk flags
- Potential increase in recruitment costs (15-20%) for skilled medical labor
- Supply chain risks for specialized medical consumables
Key Highlights
Revenue from operations increased 36.9% YoY to ₹91.72 cr from ₹67.0 cr in June 2025.
Net profit for the quarter more than doubled to ₹16.57 cr compared to ₹8.0 cr in the previous year's corresponding quarter.
Earnings Per Share (EPS) rose significantly to ₹1.02 from ₹0.46 YoY.
Total expenses for the quarter stood at ₹71.15 cr, with employee benefit expenses rising to ₹19.54 cr.
The company maintained a strong EBITDA margin of approximately 31%, consistent with its high-end specialty focus.
👀 What to Watch
Investors should monitor the bed occupancy rates of the newly operationalized 200-bed block and the revenue contribution from high-margin transplant and neuro-science programs in upcoming quarters.
120% PAT Growth: KMC Speciality Hospitals Reports ₹16.57 Cr Net Profit in Q1 FY27
KMC Speciality Hospitals reported a robust Q1 FY27 with revenue from operations growing 36.9% YoY to ₹91.72 Cr, up from ₹67.01 Cr in Q1 FY26. Net profit surged 119.8% YoY to ₹16.57 Cr, significantly outpacing revenue growth and reflecting strong operating leverage. The company's EPS for the quarter rose to ₹1.02 from ₹0.46 in the year-ago period. This performance follows the operationalization of their new 200-bed block, which appears to be driving higher margins and volume.
Confidence: HIGH
What changedThe company has delivered a significant step-up in quarterly profitability, with PAT increasing from a ₹7-15 Cr range in previous quarters to ₹16.57 Cr.
Why it mattersThe results validate the company's expansion strategy and its ability to generate high margins (OPM ~30%) from specialized tertiary care services like transplants and neurosciences.
Revenue (Q1 FY27): ₹91.72 CrNet Profit (Q1 FY27): ₹16.57 CrYoY Revenue Growth: 36.9%YoY PAT Growth: 119.8%EPS (Q1 FY27): ₹1.02
📅 Short termThe stock is likely to react positively to the strong earnings beat and the sharp expansion in net profit margins.
📈 Long termThe company is successfully scaling its 450-bed capacity in Trichy, with specialized programs providing a structural moat in the regional healthcare market.
⚠ Risk flags
- Geographic concentration in the Trichy region
- Potential 15-20% increase in recruitment costs for skilled medical labor
Key Highlights
Revenue from operations increased 36.9% YoY to ₹91.72 Cr from ₹67.01 Cr.
Net profit for the quarter grew 119.8% YoY to ₹16.57 Cr compared to ₹7.54 Cr.
Earnings Per Share (EPS) more than doubled to ₹1.02 from ₹0.46 YoY.
Total income for the quarter stood at ₹93.52 Cr, including ₹1.80 Cr of other income.
Total expenses were contained at ₹71.15 Cr, despite the scale-up in operations.
👀 What to Watch
Investors should monitor the occupancy rates of the new 200-bed Mother & Child care block and the sustainability of the current ~30% operating margins as the facility matures.
